BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74 [PMID: 36683719 DOI: 10.3748/wjg.v29.i1.61]
URL: https://www.wjgnet.com/1007-9327/full/v29/i1/61.htm
Number Citing Articles
1
J.A. Velarde-Ruiz Velasco, J. Crespo, A. Montaño-Loza, J.M. Aldana-Ledesma, A.D. Cano-Contreras, E. Cerda-Reyes, N.J. Fernández Pérez, G.E. Castro-Narro, E.S. García-Jiménez, J.E. Lira-Vera, Y.I. López-Méndez, J. Meza-Cardona, R. Moreno-Alcántar, J. Pérez-Escobar, J.L. Pérez-Hernández, D.K. Tapia-Calderón, F. Higuera-de-la-Tijera. Position paper on perioperative management and surgical risk in the patient with cirrhosisRevista de Gastroenterología de México (English Edition) 2024; 89(3): 418 doi: 10.1016/j.rgmxen.2024.05.001
2
Maxine W. Stachel, Eugene C. DePasquale. Optimizing cardiac status in the preliver transplant candidateCurrent Opinion in Organ Transplantation 2024; 29(1): 50 doi: 10.1097/MOT.0000000000001119
3
Wanting Yang, Gaoyue Guo, Chao Sun. Therapeutic potential of rifaximin in liver diseasesBiomedicine & Pharmacotherapy 2024; 178: 117283 doi: 10.1016/j.biopha.2024.117283
4
Larisse Longo, Gabriel Guerreiro, Luiza Behrens, Matheus Pereira, Carlos Pinzon, Carlos Cerski, Carolina Uribe‑Cruz, Mário Álvares‑da‑Silva. Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal modelBiomedical Reports 2024; 22(1) doi: 10.3892/br.2024.1882
5
Aldo Torre, Jacqueline Córdova-Gallardo, Alberto C Frati Munari. Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease ModifierTherapeutics and Clinical Risk Management 2023; : 839 doi: 10.2147/TCRM.S425292
6
J.A. Velarde-Ruiz Velasco, J. Crespo, A. Montaño-Loza, J.M. Aldana-Ledesma, A.D. Cano-Contreras, E. Cerda-Reyes, N.J. Fernández Pérez, G.E. Castro-Narro, E.S. García-Jiménez, J.E. Lira-Vera, Y.I. López-Méndez, J. Meza-Cardona, R. Moreno-Alcántar, J. Pérez-Escobar, J.L. Pérez-Hernández, D.K. Tapia-Calderón, F. Higuera-de-la-Tijera. Posicionamiento sobre manejo perioperatorio y riesgo quirúrgico en el paciente con cirrosisRevista de Gastroenterología de México 2024; 89(3): 418 doi: 10.1016/j.rgmx.2024.05.001
7
Xiangfeng Zeng, Sheiladevi Sukumaran. Research progress on the relationship between intestinal flora and liver cirrhosisInternational Conference on Modern Medicine and Global Health (ICMMGH 2023) 2023; : 87 doi: 10.1117/12.2692644
8
Yong He, Lu Chai, Han Chen, Xing-Shun Qi. Effect of different infusion approaches on safety and efficacy of terlipressin: Current controversiesWorld Chinese Journal of Digestology 2023; 31(17): 705 doi: 10.11569/wcjd.v31.i17.705
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
9
Christos Siafarikas, Chris J. Kapelios, Margarita Papatheodoridi, John Vlachogiannakos, Nikolaos Tentolouris, George Papatheodoridis. Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic useLiver International 2024; 44(4): 884 doi: 10.1111/liv.15851
10
Xue Li, Shi Liu, Jin Li, Ning Liu, Hui Li, An Ge, Liang Wang, Xie Dong, Hui Wang, Ju Liu, Lin Zhang, Hao Dong Zhang, Wei Gou. Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal HypertensionInternational Journal of General Medicine 2024; : 1493 doi: 10.2147/IJGM.S453107